Home > Healthcare > Medical Devices > Diagnostic Devices > Tuberculosis Diagnostics Test Market

Tuberculosis Diagnostics Test Market Share

Report ID: GMI7892
Published Date: Jan 2024
Report Format: PDF

Download Free Sample

Tuberculosis Diagnostics Test Market Share

The tuberculosis diagnostics test industry is consolidated, with key players including Abbott Laboratories, Becton, Dickinson and Company (BD), F. Hoffmann-La Roche Ltd, Qiagen N.V., and others dominating the market. These companies focus on ongoing product innovation, geographical expansion, and partnerships to secure substantial market shares.

For instance, in January 2023, QIAGEN announced an exclusive strategic collaboration with Helix, a population genomics leader based in California, aimed at advancing companion diagnostics for hereditary diseases. In this partnership, QIAGEN leveraged its biopharma relationships, Next-Generation Sequencing (NGS) capabilities, and global regulatory expertise through the Helix Laboratory Platform. The collaboration marked a significant step forward, enhancing critical access to genomic testing for patients and healthcare providers combating life-threatening conditions. Additionally, it positioned QIAGEN with a competitive edge in the diagnostic market.

Tuberculosis Diagnostics Test Market Companies

Some of the eminent market participants operating in the tuberculosis diagnostics test industry include:

Abbott Laboratories
Becton, Dickinson and Company (BD)
bioMerieux SA
Cepheid (Danaher Corporation)
F. Hoffmann-La Roche Ltd.
Hologic, Inc.
Hain Lifescience GmbH
Oxford Immunotec (PerkinElmer)
Qiagen N.V.
Roche Molecular Systems Inc.
Siemens Healthineers AG
Thermo Fisher Scientific Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global tuberculosis diagnostics test industry was valued at USD 2.3 billion in 2023 and is estimated to reach USD 3.7 billion by 2032, owing to the rising prevalence of TB.

The pathological laboratories segment garnered USD 1.20 billion revenue in 2023, attributed to the crucial role in conducting sophisticated diagnostic tests, including Nucleic Acid Amplification Tests (NAATs), molecular assays, and other pathological screening.

U.S. tuberculosis diagnostics test market accounted for USD 846 million in 2023 and is predicted to witness substantial growth through 2032, favored by the advanced healthcare infrastructure, a robust R&D landscape, and a high prevalence of TB in the region.

Abbott Laboratories, Thermo Fisher Scientific Inc., Becton, Dickinson and Company (BD), Siemens Healthineers AG., bioM